The recognition and initial management of ovarian cancer: A commented analysis of the document prepared by the National Institute for Health and Clinical Excellence (NICE);"The recognition and initial management of ovarian cancer": un'analisi commentata del documento preparato dal National Institute for Health and Clinical Excellence (NICE)

Biochimica Clinica

Volumn 37, Issue 3, 2013, Pages 220-228

  Sandri, Maria Teresa ^a   Bottari, Fabio ^a   Franchi, Dorella ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER THERAPY; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE SYSTEM; OVARY CANCER; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE;

EID: 84880862114     PISSN: 03930564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. National Institute for Health and Clinical Excellence. Ovarian cancer: The recognition and initial management of ovarian cancer. (Clinical guideline 122) 2011. www.nice.org.uk/CG122.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
4. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
5. Fleming GF, Ronnett BM, Seidman J. Epithelial ovarian cancer. In: Barakat RR, Markman M, Randall ME, et al. eds. Principles and practice of gynaecologic oncology, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2009:763- 836.
6. Morch LS, Lokkegaard E, Adreasen AH, et al. Hormone therapy and ovarian cancer. JAMA 2009;302:298-305.
7. Lin HW, Tu YY, Lin SY, et al. Risk of ovarian cancer in women with pelvic inflammatory disease: A populationbased study. Lancet Oncol 2011;12:900-4.
8. Van Leeuwen FE, Klip SY, Mooji TM, et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod 2011;26:3456-65.
9. Daly MB, Axilbund JE, Buys S, et al. Genetic/familial highrisk assessment: breast and ovarian. J Natl Compr Canc Netw 2010;8:562-94.
10. Walsh CS, Blum A, Walts A, et al. Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening. Gynecol Oncol 2010;116:516-21.
11. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967-75.
12. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:80-7.
13. Collins IM, Domchek SM, HuntsmanDG, et al. The tubal hypothesis of ovarian cancer:caution needed. Lancet Oncol 2011;12:1089-91.
14. Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011;42:918-31.
15. Carlson JW, Miron A, Jarboe EA, et al. Serous tubal intraepithelial carcinoma: Its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008;26:4160-5.
16. Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: Possibilities for earlier detection. Cancer 2007;109:221-7.
17. Bankhead CR, Kehoe ST, Austoker J. Symptoms associated with diagnosis of ovarian cancer: A systematic review. Br J Obstet Gynaecol 2005;112:857-65.
18. Fruchter RG, Boyce J. Delays in diagnosis and stage of disease in gynecologic cancer. Cancer Detect Prev 1981; 4:481-6.
19. Menczer J, Chetrit A, Sadetzki S, et al. The effect of symptom duration in epithelial ovarian cancer on prognostic factors. Arch Gynecol Obstet 2009;279:797- 801.
20. Goff BA, Mandel L, Muntz HG, et al. Ovarian carcinoma diagnosis. Cancer 2000;89:2068-75.
21. Olsen CM, Cnossen J, Green AC, et al. Comparison of symptoms and presentation of women with benign, low malignant potential and invasive ovarian tumors. Eur J Gynaecol Oncol 2007;28:376-80.
22. Robinson E, Mohilever J, Zidan J, et al. Delay in diagnosis of cancer. Possible effects on the stage of disease and survival. Cancer 1984;54:1454-60.
23. Webb PM. Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer. Gynecol Oncol 2004;92:232-9.
24. Myers ER, Bastian LA, Havrilesky LJ, et al. Management of adnexal masses. Evid Rep Technol Assess 2006;130:1- 145.
25. Liu J, Xu Y, Wang J. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis of ovarian carcinoma. Eur J Radiol 2007;62:328-34.
26. Hamilton W, Peters TJ, Bankhead C, et al. Risk of ovarian cancer in women with symptoms in primary care: Population based case-control study. Br Med J 2009;339:b2998.
27. National Cancer Institute. Groups say common symptoms may indicate ovarian cancer. http://www.cancer. gov/aboutnci/ncicancerbullettin/archive/2007/ 062607/page4.
28. Kurman RJ, Shih EM. The origin and pathogenesis of epithelial ovarian cancer: A proposed and unifying theory. Am J Surg Pathol 2010;34:433-4.
29. Seidman JD, Zhao P, Yemelyanova A. "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening ovarian cancer. Gynecol Oncol 2011;120:470-3.
30. Menon U, Gentry-Maharaj, A, Hallet R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: Results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327-40.
31. Abdel-Azeez HA, Labib HA, Sharaf SM, et al. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev 2010;11:111-6.
32. Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009;100:1315-9.
33. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402-8.
34. Nolen B, Velikokhatnaya L, Marrangoni A, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 2010;117:440-5.
35. Shah CA, Lowe KA, Paley P, et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev 2009;18:1365-72.
36. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40-6.
37. RCOG guideline: management of suspected ovarian masses in pre-menopausal women. Dec 2011. Green top
38. Available at: http://www.RCOG.org.uk.
39. Geomini P, Kruitwagen R, Bremer GL, et al. The accuracy of risk scores in predicting ovarian malignancy: A systematic review. Obstet Gynecol 2009;113:384-94.
40. Jacobs I, Oram D, Fairbanks J, et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922-9.
41. Timmerman D, Van Calster B, Jurkovic D, et al. Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors. J Clin Oncol 2007;25:4194-200.
42. Valentin L, Hagen B, Tingulstad S, et al. Comparison of "pattern recognition" and logistic regression models for discrimination between benign and malignant pelvic masses: A prospective cross validation. Ultrasound Obstet Gynecol 2001;18:357-65.
43. Timmermann D, Testa AC, Bourne T, et al. Logistic regression model to distinguish between benign and malignant adnexal mass before surgery: A multi center study by the International Ovarian Tumor Analysis Group. J Clin Oncol 2005;23:8794-801.
44. Di Legge A, Testa AC, Ameye L, et al. Lesion size affects diagnostic performance of IOTA logistic regression models, IOTA simple rules and risk of malignancy index in discriminating between benign and malignant adnexal masses. Ultrasound Obstet Gynecol 2012;40:345-54.
45. Kinkel K, Hricak H, Lu Y, et al. US characterization of ovarian masses: A meta-analysis. Radiology 2000;217:803-11.
46. Kinkel K, Lu Y, Mehdizade A, et al. Indeterminate ovarian mass at US: Incremental value of second imaging test for characterization-meta-analysis and Bayesan analysis. Radiology 2005;236:85-94.
47. Medeiros MR, Rosa DD, da Rosa MI, et al. Accuracy of ultrasonography with color Doppler in ovarian tumor: A systematic quantitative review. Int J Gynecol Cancer 2009;19:1214-20.
48. Forstner R, Sala E, Kinkel K, et al. ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol 2010;20:2773-80.